Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1090-1097

  Thomas, George P ^a   Ferrier, Gregory R ^a   Howlett, Susan E ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; LOSARTAN;

ACIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GUINEA PIG; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REFRACTORY PERIOD; HEART MUSCLE REPERFUSION; HEART VENTRICLE INFARCTION; HYPERKALEMIA; MALE; NONHUMAN; PRIORITY JOURNAL;

ANGIOTENSIN II; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BIPHENYL COMPOUNDS; ELECTRIC STIMULATION; ENDOCARDIUM; GUINEA PIGS; HEART CONDUCTION SYSTEM; IMIDAZOLES; LOSARTAN; MALE; MYOCARDIAL ISCHEMIA; RECEPTORS, ANGIOTENSIN; REPERFUSION INJURY; TETRAZOLES;

EID: 0030440929     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. BERTOLINO, F., VALENTIN, J. P., MAFFRE, M., JOVER, B., BESSAC, A. M. AND JOHN, G. W.: Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J. Pharmacol. Exp. Ther. 268: 747-752, 1994.
2. BUMPUS, F. M.: Angiotensin I and II: Some early observations made at the Cleveland Clinic Foundation and recent discoveries relative to angiotensin II formation in human heart. Hypertension 18: suppl. III, III-122-III-125, 1991.
3. CARINI, D. J., DUNCIA, J. V., ALDRICH, P. E., CHIU, A. T., JOHNSON, A. L., PIERCE, M. E., SANTELLA, J. B., WELLS, G. J., WEXLER, R. R., WONG, P. C. AND TIMMERMANS, P. B. M. W. M.: Nonpeptide angiotensin II receptor antagonists: the discovery of a series of n-(biphenylmethyl) imidazoles as potent, orally-active antihypertensives. J. Med. Chem. 34: 2525-2547, 1991.
4. CHANSEL, D., BADRE, L., CZEKALSKI, S. VANDERMEERSCH, S., CAMBAR, J. AND ARDAILLOU, R.: Intrinsic properties of a nonpeptide angiotensin II antagonist losartan in glomeruli and mesangial cells at high concentrations. J. Pharmacol. Exp. Ther. 265: 1534-1543, 1993.
5. CHIU, A. T., MCCALL, D. E., PRICE, W. A. JR., WONG, P. C., CARINI, D. J., DUNCIA, J. V., WEXLER, R. R., YOO, S. E., JOHNSON, A. L. AND TIMMERMANS, P. B. M. W. M.: Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 252: 711-718, 1990.
6. CLELAND, J. G. F., DARGIE, H. J., BALL, S. G., GILLEN, G., HODSMAN, G. P., MORTON, J. J., EAST, B. W., ROBERTSON, I., FORD, I. AND ROBERTSON, J. I. S.: Effects of enalapril in heart failure: A double blind study of effects on exercise performance, renal function, hormones and metabolic state. Br. Heart J. 54: 305-312, 1985.
7. DE MELLO, W. C.: Effect of intracellular injection of calcium and strontium on cell communication in heart. J. Physiol. (Lond) 263: 171-197, 1975.
8. EBERHARDT, R. T., KEVAK, R. M., KANG, P. M. AND FRISHMAN, W. H.: Angiotensin II receptor blockade: An innovative approach to cardiovascular pharmacotherapy. J. Clin. Pharmacol. 33: 1023-1038, 1993.
9. FEIDLER, V. B. AND MARDIN, M.: Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death. Basic Res. Cardiol. 81: 40-53, 1986.
10. FERRIER, G. R. AND GUYETTE, C. M.: Ventricular tachycardia in an isolated guinea-pig ventricular free wall model of ischemia and reperfusion. J. Cardiovasc. Pharmacol. 17: 228-238, 1991.
11. FERRIER, G. R., MOFFAT, M. P. AND LUKAS, A.: Possible mechanisms of ventricular arrhythmias elicited by ischemia followed by reperfusion: Studies on isolated canine ventricular tissues. Circ. Res. 56: 184-194, 1985.
12. GOOD, J. M., NIHOYANNOPOULOS, P., GHATEI, M. A., CROSSMAN, D., BLOOM, S. R., CLARKE, P., OAKLEY, C. M. AND CLELAND, J. G. F.: Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II. Eur. Heart J. 15: 1634-1640, 1994.
13. JAISWAL, N., DIZ, D. I., TALLANT, A., KOSLA, M. C. AND FERRARIO, C. M.: The nonpeptide angiotensin II antagonist DnP 753 is a potent stimulus for prostacyclin synthesis. Am. J. Hypertension 4: 228-233, 1991.
14. KANG, P. M., LANDAU, A. J., EBERHARDT, R. T. AND FRISHMAN, W. H.: Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system. Am. Heart J. 127: 1388-1401, 1994.
15. i in single heart cells. Am. J. Physiol. 261: H1115-H1122, 1991.
16. LI, G. R. AND FERRIER, G. R.: Effects of quinidine on arrhythmias and conduction in an isolated tissue model of ischemia and reperfusion. J. Cardiovasc. Pharmacol. 17: 239-248, 1991.
17. LI, G. R. AND FERRIER, G. R.: Verapamil prevents slowing of transmural conduction and suppresses arrhythmias in an isolated guinea pig ventricular model of ischemia and reperfusion. Circ. Res. 70: 651-659, 1992.
18. LINZ, W. AND SCHOLKENS, B. A.: Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts. J. Cardiovasc. Pharmacol. 10: suppl. 7, S75-S82, 1987.
19. MOFFAT M. P., FERRIER, G. R. AND KARMAZYN, M.: A direct role of endogenous prostaglandins in reperfusion-induced cardiac arrhythmias. Can. J. Physiol. Pharmacol. 67: 772-779, 1989.
20. NEELY, J. R. AND MORGAN, M. J.: Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu. Rev. Physiol. 36: 413-459, 1974.
21. PALS, D. T., MASUCCI, F. E., SIPOS, F. AND DENNING, G. S. JR.: A specific competitive antagonist of the vascular action of angiotensin II. Circ. Res. 29: 664-672, 1971.
22. PARRATT, J.: Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc. Res. 27: 693-702, 1993.
23. ROCHETTE, L., RIBUOT, C., BELICHARD, P., BRIL, A. AND DEVISSAGUET M.: Protective effect of angiotensin converting enzyme inhibitors (CEI): Captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion in rat. Clin. Exp. Hypertension A 9: 365-368, 1987.
24. SAS INSTITUTE INC.: SAS/STAT User's Guide, 4th ed., version 6, vol. 2, SAS Institute Inc., Cary, NC, 1990.
25. SIGURDSSON, A., HELD, P. AND SWEDBERG, K.: Short- and long-term neurohormonal activation following acute myocardial infarction. Am. Heart J. 126: 1068-1076, 1993.
26. SMITH, R. D., CHIU, A. T., WONG, P. C., HERBLIN, W. F. AND TIMMERMANS, P. B. M. W. M.: Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu. Rev. Pharmacol. Toxicol. 32: 135-165, 1992.
27. STREETEN, D. H., ANDERSON, G. H., FREIBURG, J. M. AND DALAKOS, T. G.: Use of angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension. N. Engl. J. Med. 292: 657-662, 1975.
28. THOMAS, G. P., HOWLETT, S. E. AND FERRIER, G. R.: Saralasin suppresses arrhythmias in an isolated guinea-pig ventricular free wall model of simulated ischemia and reperfusion. J. Pharmacol. Exp. Ther. 274: 1379-1386, 1995.
29. TIMMERMANS, P. B. M. W. M., WONG, P. C., CHIU, A. T., HERBLIN, W. F., BENFIELD, P., CARINI, D. J., LEE, R. J., WEXLER, R. R., SAYE, J. A. M. AND SMITH, R. D.: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45: 205-251, 1993.
30. URATA, H., HEALY, B., STEWART, R. W., BUMPUS, F. M. AND HUSSAIN, A.: Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 66: 883-890, 1990.
31. WAKS, U. A., MAXWELL, M. H., MARKS, L., ZAWADA, E. T. AND KAUFMAN, J. J.: Pressor response to saralasin (1-sar-8-ala-angiotensin II) bolus injection in hypertensive patients. Circulation 27: 1165-1170, 1978.